 Novartis AG NYSE: NVS said that Kesimpta ofatumumab had won European Union approval as the first and only self-administered, targeted B-cell therapy for adult patients with relapsing multiple sclerosis. The company is developing and marketing the product under a license agreement with Genmab AS NASDAQ: GMAB. 